Synthesis and evaluation of 11C-labeled naphthalene derivative as a novel non-peptidergic probe for the β-secretase (BACE1) imaging in Alzheimer's disease brain

Nuclear Medicine and Biology

Volumn 40, Issue 5, 2013, Pages 705-709

  Kawai, Tomoki ^a   Kawashima, Hidekazu ^a,b   Kuge, Yuji ^a,c   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Secretase; Alzheimer's disease; In vivo imaging; Positron emission tomography (PET)

Indexed keywords

BETA SECRETASE 1; NAPHTHALENE 1 CARBOXYLIC ACID [3'CHLORO 4' FLUORO 4 (4 METHYLPIPERAZIN 1 YL)BIPHENYL 3 YL]AMIDE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANILIDE; CARBON; DIAGNOSTIC AGENT; NAPHTHALENE; NAPHTHALENE 1 CARBOXYLIC ACID (3' CHLORO 4' FLUORO 4 PIPERAZIN 1 YL BIPHENYL 3 YL)AMIDE; NAPHTHALENE DERIVATIVE; NAPHTHALENE-1-CARBOXYLIC ACID (3'-CHLORO-4'-FLUORO-4-PIPERAZIN-1-YL-BIPHENYL-3-YL)AMIDE; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; FLUORESCENCE RESONANCE ENERGY TRANSFER; IC 50; ISOTOPE LABELING; LIPOPHILICITY; MALE; MOUSE; NEUROIMAGING; NONHUMAN; PLASMA CLEARANCE; RADIOCHEMISTRY; RADIOISOTOPE DECAY; ANIMAL; CHEMISTRY; ENZYMOLOGY; KINETICS; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; RAT; SYNTHESIS; DIAGNOSTIC USE; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANILIDES; ANIMALS; BRAIN; CARBON RADIOISOTOPES; CHEMISTRY TECHNIQUES, SYNTHETIC; KINETICS; MALE; MICE; MOLECULAR IMAGING; NAPHTHALENES; RADIOCHEMISTRY; RATS;

EID: 84878178825     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.03.008     Document Type: Article

References (22)

1. Sinha S., Anderson J.P., Barbour R., Basi G.D., Caccavello R., Davis D., et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999, 402:537-540.
2. Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., et al. β-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci 2007, 27:3639-3649.
3. McConlogue L., Buttini M., Anderson J.P., Brigham E.F., Chen K.S., Freedman S.B., et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. J Biol Chem 2007, 282:26326-26334.
4. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 2002, 59:1381-1389.
5. Yang L.B., Lindholm K., Yan R., Citron M., Xia W., Yang X.L., et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med 2003, 9:3-4.
6. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A.K., et al. Structure of the protease domain of memapsin 2 (β-secretase) complexed with inhibitor. Science 2000, 290:150-153.
7. Kimura T., Shuto D., Kasai S., Liu P., Hidaka K., Hamada T., et al. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine. Bioorg Med Chem Lett 2004, 14:1527-1531.
8. Kimura T., Shuto D., Hamada Y., Igawa N., Kasai S., Liu P., et al. Design and synthesis of highly active Alzheimer's β-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 2005, 15:211-215.
9. Asai M., Hattori C., Iwata N., Saido T.C., Sasagawa N., Szabό B., et al. The novel β-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006, 96:533-540.
10. Bhisetti GR, Saunders JO, Murcko MA, Lepre CA, Britt SD, Come JH, et al. Inhibitors of BACE. WO/ 2002/088101, 2002.
11. 11C]methyl triflate. Appl Radiat Isot 1992, 43:1383-1385.
12. Ono M., Kawashima H., Nonaka A., Kawai T., Haratake M., Mori H., et al. Novel benzofuran derivatives for PET imaging of β-amyloid plaques in Alzheimer's disease brains. J Med Chem 2006, 49:2725-2730.
13. Oldendorf W.H. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 1970, 24:372-376.
14. Fukumoto H., Cheung B.S., Hyman B.T., Irizarry M.C. β-Secretase protein and activity are increased in the neocortex in Alzheimer's disease. Arch Neurol 2002, 59:1381-1389.
15. Holsinger R.M., McLean C.A., Beyreuther K., Masters C.L., Evin G. Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann Neurol 2002, 51:783-786.
16. Chen C.H., Zhou W., Liu S., Deng Y., Cai F., Tone M., et al. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2012, 15:77-90.
17. Fukumoto H., Rosene D.L., Moss M.B., Raju S., Hyman B.T., Irizarry M.C. β-Secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004, 164:719-725.
18. Ahmed R.R., Holler C.J., Webb R.L., Li F., Beckett T.L., Murphy M.P. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 2010, 112:1045-1053.
19. Zhao J., Fu Y., Yasvoina M., Shao P., Hitt B., O'Connor T., et al. β-Site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer disease pathogenesis. J Neurosci 2007, 27:3639-3649.
20. +. Jpn J Pharmacol 2002, 89:426-428.
21. Chou C.H., McLachlan A.J., Rowland M. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J Pharmacol Exp Ther 1995, 275:933-940.
22. Dischino D.D., Welch M.J., Kilbourn M.R., Raichle M.E. Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med 1983, 24:1030-1038.